View Item 

Show simple item record

ACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas
dc.contributor.authorBeitler, Jonathan J.
dc.contributor.authorQuon, Harry
dc.contributor.authorJones, Christopher U.
dc.contributor.authorSalama, Joseph K.
dc.contributor.authorBusse, Paul M.
dc.contributor.authorCooper, Jay S.
dc.contributor.authorKoyfman, Shlomo A.
dc.contributor.authorRidge, John A.
dc.contributor.authorSaba, Nabil F.
dc.contributor.authorSiddiqui, Farzan
dc.contributor.authorSmith, Richard V.
dc.contributor.authorWorden, Francis
dc.contributor.authorYao, Min
dc.contributor.authorYom, Sue S.
dc.date.accessioned2016-09-17T23:54:33Z
dc.date.available2017-12-01T21:54:11Zen
dc.date.issued2016-09
dc.identifier.citationBeitler, Jonathan J.; Quon, Harry; Jones, Christopher U.; Salama, Joseph K.; Busse, Paul M.; Cooper, Jay S.; Koyfman, Shlomo A.; Ridge, John A.; Saba, Nabil F.; Siddiqui, Farzan; Smith, Richard V.; Worden, Francis; Yao, Min; Yom, Sue S. (2016). "ACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas." Head & Neck 38(9): 1299-1309.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/133590
dc.description.abstractBackgroundThere are no level I studies to guide treatment for resectable oropharyngeal squamous cell carcinoma (SCC). Treatment toxicities influence management recommendations. Ongoing investigations are examining deintensified treatments for human papillomavirus (HPV)‐associated oropharyngeal SCC.MethodsThe Appropriateness Criteria panel, using modified Delphi methodology, produced a literature summary, an assessment of treatment recommendations, and cases to illustrate their use.ResultsA multidisciplinary team produces optimum results. Based on HPV status, smoking history, and staging, patients are divided into groups at low, intermediate, and high‐risk of death. In the future, treatment recommendations may be influenced by HPV status, which has changed the epidemiology of oropharyngeal SCC.ConclusionT1 to T2N0M0 resectable oropharyngeal SCC can be treated with surgery or radiation without chemotherapy. Patients with T1‐2N1‐2aM0 disease can receive radiation, chemoradiation, or transoral surgery with neck dissection and appropriate adjuvant therapy. Patients with T1‐2N2b‐3M0 disease should receive chemoradiation or transoral surgery with neck dissection and appropriate adjuvant therapy. Concurrent chemoradiation is preferred for T3 to T4 disease. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1299–1309, 2016
dc.publisherWiley Periodicals, Inc.
dc.subject.othertransoral robotic surgery (TORS)
dc.subject.othertonsillar cancer
dc.subject.otherbase of tongue cancer
dc.subject.otheroropharyngeal cancer
dc.subject.otherhuman papillomavirus (HPV)
dc.titleACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/133590/1/hed24447.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/133590/2/hed24447_am.pdf
dc.identifier.doi10.1002/hed.24447
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceBeckmann GK, Hoppe F, Pfreundner L, Flentje MP. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005; 27: 36 – 43.
dc.identifier.citedreferenceChen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys 2008; 71: 1356 – 1364.
dc.identifier.citedreferenceUygun K, Bilici A, Karagol H, et al. The comparison of weekly and three‐weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non‐metastatic squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2009; 64: 601 – 605.
dc.identifier.citedreferenceHo KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3‐weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 2008; 47: 1513 – 1518.
dc.identifier.citedreferenceRades D, Fehlauer F, Sheikh–Sarraf M, et al. Toxicity of two cisplatin‐based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck 2008; 30: 235 – 241.
dc.identifier.citedreferenceSteinmann D, Cerny B, Karstens JH, Bremer M. Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head‐and‐neck cancer patients: a cumulative dose‐effect analysis. Strahlenther Onkol 2009; 185: 682 – 688.
dc.identifier.citedreferenceTraynor AM, Richards GM, Hartig GK, et al. Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck 2010; 32: 599 – 606.
dc.identifier.citedreferenceBourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99‐02): an open‐label phase 3 randomised trial. Lancet Oncol 2012; 13: 145 – 153.
dc.identifier.citedreferenceNguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol 2002; 3: 693 – 701.
dc.identifier.citedreferenceMoreno–Jiménez M, Valero J, López–Picazo JM, et al. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules. Am J Clin Oncol 2010; 33: 137 – 143.
dc.identifier.citedreferenceSemrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5‐fluorouracil: updated results of a randomized multicentric trial in advanced head‐and‐neck cancer. Int J Radiat Oncol Biol Phys 2006; 64: 1308 – 1316.
dc.identifier.citedreferenceBonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‐year survival data from a phase 3 randomised trial, and relation between cetuximab‐induced rash and survival. Lancet Oncol 2010; 11: 21 – 28.
dc.identifier.citedreferenceBonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous‐cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567 – 578.
dc.identifier.citedreferenceAng KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014; 32: 2940 – 2950.
dc.identifier.citedreferenceHarari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high‐risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG‐0234. J Clin Oncol 2014; 32: 2486 – 2495.
dc.identifier.citedreferencePosner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705 – 1715.
dc.identifier.citedreferenceVermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695 – 1704.
dc.identifier.citedreferencePointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5‐fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498 – 506.
dc.identifier.citedreferenceHitt R, López–Pousa A, Martínez–Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636 – 8645.
dc.identifier.citedreferenceBlanchard P, Bourhis J, Lacas B, et al. Taxane‐cisplatin‐fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta‐analysis of the meta‐analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013; 31: 2854 – 2860.
dc.identifier.citedreferenceBeitler JJ, Cooper JS. Seduction by induction? J Clin Oncol 2009; 27: 9 – 10.
dc.identifier.citedreferenceCohen EE, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014; 32: 2735 – 2743.
dc.identifier.citedreferenceHaddad R, O’Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013; 14: 257 – 264.
dc.identifier.citedreferenceHitt R, Grau JJ, López–Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014; 25: 216 – 225.
dc.identifier.citedreferencePaccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21: 1515 – 1522.
dc.identifier.citedreferenceGrant DG, Salassa JR, Hinni ML, Pearson BW, Perry WC. Carcinoma of the tongue base treated by transoral laser microsurgery, part one: untreated tumors, a prospective analysis of oncologic and functional outcomes. Laryngoscope 2006; 116: 2150 – 2155.
dc.identifier.citedreferenceLaccourreye O, Hans S, Ménard M, Garcia D, Brasnu D, Holsinger FC. Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: II. An analysis of the incidence, related variables, and consequences of local recurrence. Arch Otolaryngol Head Neck Surg 2005; 131: 592 – 599.
dc.identifier.citedreferenceSteiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2003; 129: 36 – 43.
dc.identifier.citedreferenceWeinstein GS, O’Malley BW Jr, Snyder W, Sherman E, Quon H. Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg 2007; 133: 1220 – 1226.
dc.identifier.citedreferencePeters LJ, Goepfert H, Ang KK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993; 26: 3 – 11.
dc.identifier.citedreferenceBernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945 – 1952.
dc.identifier.citedreferenceCooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high‐risk squamous‐cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937 – 1944.
dc.identifier.citedreferenceMarur S, Li S, Cmelak A, et al. E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)‐associated resectable squamous cell carcinoma of the oropharynx (OPSCC). J Clin Oncol 2013; 31 ( Suppl ): abstract #6005.
dc.identifier.citedreferenceNCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. Version 2.2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/head‐and‐neck.pdf. Accessed March 26, 2015.
dc.identifier.citedreferenceCaudell JJ, Schaner PE, Meredith RF, et al. Factors associated with long‐term dysphagia after definitive radiotherapy for locally advanced head‐and‐neck cancer. Int J Radiat Oncol Biol Phys 2009; 73: 410 – 415.
dc.identifier.citedreferenceLangendijk JA, Doornaert P, Rietveld DH, Verdonck–de Leeuw IM, Leemans CR, Slotman BJ. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 2009; 90: 189 – 195.
dc.identifier.citedreferenceMachtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582 – 3589.
dc.identifier.citedreferenceLangendijk JA, Doornaert P, Verdonck–de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment‐related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26: 3770 – 3776.
dc.identifier.citedreferenceGillison ML. Human papillomavirus‐associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004; 31: 744 – 754.
dc.identifier.citedreferenceErnster JA, Sciotto CG, O’Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007; 117: 2115 – 2128.
dc.identifier.citedreferenceChien CY, Su CY, Fang FM, et al. Lower prevalence but favorable survival for human papillomavirus‐related squamous cell carcinoma of tonsil in Taiwan. Oral Oncol 2008; 44: 174 – 179.
dc.identifier.citedreferenceFischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 2010; 126: 1256 – 1262.
dc.identifier.citedreferenceHannisdal K, Schjølberg A, De Angelis PM, Boysen M, Clausen OP. Human papillomavirus (HPV)‐positive tonsillar carcinomas are frequent and have a favourable prognosis in males in Norway. Acta Otolaryngol 2010; 130: 293 – 299.
dc.identifier.citedreferenceKlozar J, Kratochvil V, Salakova M, et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otorhinolaryngol 2008; 265 Suppl 1: S75 – S82.
dc.identifier.citedreferenceKlussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV‐related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res 2009; 15: 1779 – 1786.
dc.identifier.citedreferenceLicitra L, Perrone F, Bossi P, et al. High‐risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630 – 5636.
dc.identifier.citedreferenceStraetmans JM, Olthof N, Mooren JJ, de Jong J, Speel EJ, Kremer B. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 2009; 119: 1951 – 1957.
dc.identifier.citedreferenceWeinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736 – 747.
dc.identifier.citedreferenceSettle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2009; 2: 776 – 781.
dc.identifier.citedreferenceWorden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26: 3138 – 3146.
dc.identifier.citedreferenceKies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8 – 14.
dc.identifier.citedreferenceGillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16‐positive and p16‐negative oropharyngeal cancer. J Clin Oncol 2012; 30: 2102 – 2111.
dc.identifier.citedreferenceRischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142 – 4148.
dc.identifier.citedreferenceLassen P, Eriksen JG, Hamilton–Dutoit S, et al. HPV‐associated p16‐expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010; 94: 30 – 35.
dc.identifier.citedreferenceFakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus‐positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261 – 269.
dc.identifier.citedreferenceHafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16‐associated tonsillar carcinomas. Int J Cancer 2008; 122: 2656 – 2664.
dc.identifier.citedreferenceMaxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus‐positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010; 16: 1226 – 1235.
dc.identifier.citedreferenceO’Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus‐related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013; 31: 543 – 550.
dc.identifier.citedreferenceAng KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24 – 35.
dc.identifier.citedreferenceHolsinger FC, McWhorter AJ, Ménard M, Garcia D, Laccourreye O. Transoral lateral oropharyngectomy for squamous cell carcinoma of the tonsillar region: I. Technique, complications, and functional results. Arch Otolaryngol Head Neck Surg 2005; 131: 583 – 591.
dc.identifier.citedreferenceMoore EJ, Henstrom DK, Olsen KD, Kasperbauer JL, McGree ME. Transoral resection of tonsillar squamous cell carcinoma. Laryngoscope 2009; 119: 508 – 515.
dc.identifier.citedreferenceWeinstein GS, Quon H, Newman HJ, et al. Transoral robotic surgery alone for oropharyngeal cancer: an analysis of local control. Arch Otolaryngol Head Neck Surg 2012; 138: 628 – 634.
dc.identifier.citedreferenceHarrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 1997; 19: 169 – 175.
dc.identifier.citedreferenceHorwitz EM, Frazier AJ, Martinez AA, et al. Excellent functional outcome in patients with squamous cell carcinoma of the base of tongue treated with external irradiation and interstitial iodine 125 boost. Cancer 1996; 78: 948 – 957.
dc.identifier.citedreferenceLevendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose‐effect relationship. Radiother Oncol 2007; 85: 64 – 73.
dc.identifier.citedreferencePernot M, Hoffstetter S, Peiffert D, et al. Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation. Otolaryngol Head Neck Surg 1996; 115: 519 – 526.
dc.identifier.citedreferencePetruson K, Mercke C, Lundberg LM, Silander E, Hammerlid E. Longitudinal evaluation of patients with cancer in the oral tongue, tonsils, or base of tongue–does interstitial radiation dose affect quality of life? Brachytherapy 2005; 4: 271 – 277.
dc.identifier.citedreferenceBudach W, Hehr T, Budach V, Belka C, Dietz K. A meta‐analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28.
dc.identifier.citedreferenceBourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta‐analysis. Lancet 2006; 368: 843 – 854.
dc.identifier.citedreferenceBeitler JJ, Zhang Q, Fu KK, et al. Final results of local‐regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2014; 89: 13 – 20.
dc.identifier.citedreferenceFu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7 – 16.
dc.identifier.citedreferenceLauve A, Morris M, Schmidt–Ullrich R, et al. Simultaneous integrated boost intensity‐modulated radiotherapy for locally advanced head‐and‐neck squamous cell carcinomas: II–clinical results. Int J Radiat Oncol Biol Phys 2004; 60: 374 – 387.
dc.identifier.citedreferenceMell LK, Mehrotra AK, Mundt AJ. Intensity‐modulated radiation therapy use in the U.S., 2004. Cancer 2005; 104: 1296 – 1303.
dc.identifier.citedreferenceEisbruch A, Harris J, Garden AS, et al. Multi‐institutional trial of accelerated hypofractionated intensity‐modulated radiation therapy for early‐stage oropharyngeal cancer (RTOG 00‐22). Int J Radiat Oncol Biol Phys 2010; 76: 1333 – 1338.
dc.identifier.citedreferenceToledano I, Graff P, Serre A, et al. Intensity‐modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004‐03. Radiother Oncol 2012; 103: 57 – 62.
dc.identifier.citedreferenceEisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 2003; 27: 832 – 837.
dc.identifier.citedreferenceLee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity‐modulated radiation therapy for head‐and‐neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 2003; 57: 49 – 60.
dc.identifier.citedreferenceSaarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 2005; 74: 251 – 258.
dc.identifier.citedreferenceChao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head‐and‐neck cancers receiving intensity‐modulated or three‐dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001; 49: 907 – 916.
dc.identifier.citedreferencePow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity‐modulated radiotherapy vs. conventional radiotherapy for early‐stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66: 981 – 991.
dc.identifier.citedreferenceNutting CM, Morden JP, Harrington KJ, et al. Parotid‐sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127 – 136.
dc.identifier.citedreferenceGrégoire V, De Neve W, Eisbruch A, Lee N, Van den Weyngaert D, Van Gestel D. Intensity‐modulated radiation therapy for head and neck carcinoma. Oncologist 2007; 12: 555 – 564.
dc.identifier.citedreferenceMendenhall WM, Amdur RJ, Palta JR. Intensity‐modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006; 24: 2618 – 2623.
dc.identifier.citedreferencePeters LJ, O’Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010; 28: 2996 – 3001.
dc.identifier.citedreferencePignon JP, le Maître A, Maillard E, Bourhis J; MACH‐NC Collaborative Group. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4 – 14.
dc.identifier.citedreferenceAdelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92 – 98.
dc.identifier.citedreferenceDenis F, Garaud P, Bardet E, et al. Final results of the 94‐01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced‐stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69 – 76.
dc.identifier.citedreferenceRodriguez CP, Adelstein DJ, Rybicki LA, et al. Randomized phase III study of 2 cisplatin‐based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. Head Neck 2015; 37: 1583 – 1589.
dc.identifier.citedreferenceQuon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of radiation therapy with or without cis‐platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys 2011; 81: 719 – 725.
dc.identifier.citedreferenceChan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy‐radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression‐free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20: 2038 – 2044.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed24447.pdf
Size:
139.2KB
Format:
PDF
View/Open
Name:
hed24447_am.pdf
Size:
404.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.